830 TCR
Alternative Names: 830-TCRLatest Information Update: 23 Oct 2023
At a glance
- Originator T-Cure
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 11 Oct 2023 Preclinical trials in Solid tumours in USA (Parenteral), prior to October 2023 (T-Cure pipeline, October 2023)